Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week

Journal of the American College of Cardiology

Volumn 72, Issue 17, 2018, Pages 2071-2081

  Libby, Peter ^a   Loscalzo, Joseph ^a   Ridker, Paul M ^a   Farkouh, Michael E ^b   Hsue, Priscilla Y ^c   Fuster, Valentin ^d   Hasan, Ahmed A ^e   Amar, Salomon ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

basic translational research

Indexed keywords

ANGIOTENSIN II; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE ASSOCIATION; FEVER; FIBRINOLYSIS; FOAM CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPOXEMIA; IMMUNE RESPONSE; IMMUNITY; INFECTION; INFLAMMATION; INNATE IMMUNITY; INTRA-ABDOMINAL FAT; MICROBIOME; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SMOKING; TACHYCARDIA; TH1 CELL; TH17 CELL; TH2 CELL; THROMBOSIS; VACCINATION; DRUG DEVELOPMENT; DRUG EFFECT; IMMUNOLOGY; RISK FACTOR;

ATHEROSCLEROSIS; DRUG DEVELOPMENT; HUMANS; IMMUNITY; INFLAMMATION; RISK FACTORS;

EID: 85054177198     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.08.1043     Document Type: Review

References (113)

1. Hansson, G.K., Jonasson, L., The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 29 (2009), 1714–1717.
2. Libby, P., History of discovery: inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32 (2012), 2045–2051.
3. Goldstein, J.L., Brown, M.S., A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161 (2015), 161–172.
4. Ross, R., Harker, L., Hyperlipidemia and atherosclerosis. Science 193 (1976), 1094–1100.
5. Ross, R., Glomset, J.A., The pathogenesis of atherosclerosis II. N Engl J Med 295 (1976), 420–425.
6. Ross, R., Glomset, J.A., The pathogenesis of atherosclerosis I. N Engl J Med 295 (1976), 369–377.
7. Liu, D.J., Peloso, G.M., Yu, H., et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet 49 (2017), 1758–1766.
8. Khera, A.V., Emdin, C.A., Drake, I., et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med 375 (2016), 2349–2358.
9. Fernandez-Friera, L., Fuster, V., Lopez-Melgar, B., et al. Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol 70 (2017), 2979–2991.
10. Ross, R., Glomset, J.A., Atherosclerosis and the arterial smooth muscle cells. Science 180 (1973), 1332–1339.
11. Benditt, E.P., Benditt, J.M., Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A 70 (1973), 1753–1756.
12. Benditt, E.P., Evidence for a monoclonal origin of human atherosclerotic plaques and some implications. Circulation 50 (1974), 650–652.
13. Benditt, E.P., Implications of the monoclonal character of human atherosclerotic plaques. Am J Pathol 86 (1977), 693–702.
14. Ross, R., Glomset, J.A., Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180 (1973), 1332–1339.
15. Aqel, N.M., Ball, R.Y., Waldmann, H., Mitchinson, M.J., Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol 146 (1985), 197–204.
16. Jonasson, L., Holm, J., Skalli, O., Bondjers, G., Hansson, G.K., Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6 (1986), 131–138.
17. Bennett, M.R., Sinha, S., Owens, G.K., Vascular smooth muscle cells in atherosclerosis. Circ Res 118 (2016), 692–702.
18. Tsukada, T., Rosenfeld, M., Ross, R., Gown, A.M., Immunocytochemical analysis of cellular components in lesions of atherosclerosis in the Watanabe and fat-fed rabbit using monoclonal antibodies. Arteriosclerosis 6 (1986), 601–613.
19. Jonasson, L., Holm, J., Skalli, O., Gabbiani, G., Hansson, G.K., Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 76 (1985), 125–131.
20. Hansson, G.K., Jonasson, L., Holm, J., Claesson-Welsh, L., Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol 64 (1986), 261–268.
21. Warner, S.J., Friedman, G.B., Libby, P., Regulation of major histocompatibility gene expression in cultured human vascular smooth muscle cells. Arteriosclerosis 9 (1989), 279–288.
22. Libby, P., Hansson, G.K., Lichtman, A.H., Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38 (2013), 1092–1104.
23. Lichtman, A.H., Binder, C.J., Tsimikas, S., Witztum, J.L., Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 123 (2013), 27–36.
24. Libby, P., Hansson, G.K., Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 116 (2015), 307–311.
25. Nus, M., Mallat, Z., Immune-mediated mechanisms of atherosclerosis and implications for the clinic. Expert Rev Clin Immunol 12 (2016), 1217–1237.
26. Clinton, S.K., Libby, P., Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 116 (1992), 1292–1300.
27. Ait-Oufella, H., Taleb, S., Mallat, Z., Tedgui, A., Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31 (2011), 969–979.
28. Libby, P., Ordovàs, J.M., Auger, K.R., Robbins, H., Birinyi, L.K., Dinarello, C.A., Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 124 (1986), 179–186.
29. Libby, P., Ordovas, J.M., Birinyi, L.K., Auger, K.R., Dinarello, C.A., Inducible interleukin-1 expression in human vascular smooth muscle cells. J Clin Invest 78 (1986), 1432–1438.
30. Charo, I.F., Ransohoff, R.M., The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354 (2006), 610–621.
31. Viola, A., Luster, A.D., Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48 (2008), 171–197.
32. Hansson, G.K., Libby, P., The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006), 508–519.
33. Swirski, F.K., Nahrendorf, M., Libby, P., Mechanisms of myeloid cell modulation of atherosclerosis. Microbiol Spectr, 4, 2016.
34. Cochain, C., Vafadarnejad, E., Arampatzi, P., et al. Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis. Circ Res 122 (2018), 1661–1674.
35. Winkels, H., Ehinger, E., Vassallo, M., et al. Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry. Circ Res 122 (2018), 1675–1688.
36. Cole, J.E., Park, I., Ahern, D., et al. Immune cell census in murine atherosclerosis: cytometry by time of flight illuminates vascular myeloid cell diversity. Cardiovasc Res 114 (2018), 1360–1371.
37. Tsiantoulas, D., Sage, A.P., Mallat, Z., Binder, C.J., Targeting B cells in atherosclerosis: closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol 35 (2015), 296–302.
38. Hilgendorf, I., Theurl, I., Gerhardt, L.M., et al. Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation 129 (2014), 1677–1687.
39. Serhan, C.N., Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J 31 (2017), 1273–1288.
40. Fredman, G., Tabas, I., Boosting inflammation resolution in atherosclerosis: the next frontier for therapy. Am J Pathol 187 (2017), 1211–1221.
41. Libby, P., Nahrendorf, M., Swirski, F.K., Leukocytes link local and systemic inflammation in ischemic cardiovascular disease. J Am Coll Cardiol 67 (2016), 1091–1103.
42. Jaiswal, S., Fontanillas, P., Flannick, J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
43. Steensma, D.P., Bejar, R., Jaiswal, S., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126 (2015), 9–16.
44. Jaiswal, S., Natarajan, P., Silver, A.J., et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377 (2017), 111–121.
45. Libby, P., Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 369 (2013), 2004–2013.
46. Hansson, G.K., Libby, P., Tabas, I., Inflammation and plaque vulnerability. J Intern Med 278 (2015), 483–493.
47. De Caterina, R., D'Ugo, E., Libby, P., Inflammation and thrombosis—testing the hypothesis with anti-inflammatory drug trials. Thromb Haemost, 116, 2016.
48. Ketelhuth, D.F., Hansson, G.K., Adaptive response of T and B cells in atherosclerosis. Circ Res 118 (2016), 668–678.
49. Kranzhofer, R., Browatzki, M., Schmidt, J., Kubler, W., Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 257 (1999), 826–828.
50. McMaster, W.G., Kirabo, A., Madhur, M.S., Harrison, D.G., Inflammation, immunity, and hypertensive end-organ damage. Circ Res 116 (2015), 1022–1033.
51. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003), 1796–1808.
52. Rocha, V.Z., Folco, E.J., Sukhova, G., et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 103 (2008), 467–476.
53. Rocha, V.Z., Folco, E.J., Ozdemir, C., et al. CXCR3 controls T-cell accumulation in fat inflammation. Arterioscler Thromb Vasc Biol 34 (2014), 1374–1381.
54. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11 (2011), 98–107.
55. Hajjar, D.P., Fabricant, C.G., Minick, C.R., Fabricant, J., Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 122 (1986), 62–70.
56. Libby, P., Tanaka, H., The molecular bases of restenosis. Prog Cardiovasc Dis 40 (1997), 97–106.
57. Muhlestein, J.B., Bacterial infections and atherosclerosis. J Investigative Med 46 (1998), 396–402.
58. Byrne, G.I., Skarlotos, S.I., Grunfeld, C., et al. Collaborative Multidisciplinary Workshop Report: interface of lipid metabolism, atherosclerosis, and Chlamydia infection. J Infect Dis 181 (2000), S490–S491.
59. Kol, A., Libby, P., The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med 8 (1998), 191–199.
60. Kol, A., Libby, P., Molecular mediators of arterial inflammation: a role for microbial products?. Am Heart J 138 (1999), S450–S452.
61. Pussinen, P.J., Tuomisto, K., Jousilahti, P., Havulinna, A.S., Sundvall, J., Salomaa, V., Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 27 (2007), 1433–1439.
62. Miller, M.A., McTernan, P.G., Harte, A.L., et al. Ethnic and sex differences in circulating endotoxin levels: a novel marker of atherosclerotic and cardiovascular risk in a British multi-ethnic population. Atherosclerosis 203 (2009), 494–502.
63. McIntyre, C.W., Harrison, L.E., Eldehni, M.T., et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 6 (2011), 133–141.
64. Thom, D.H., Grayston, J.T., Siscovick, D.S., Wang, S.P., Weiss, N.S., Daling, J.R., Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 268 (1992), 68–72.
65. Danesh, J., Collins, R., Peto, R., Chronic infections and coronary heart disease: is there a link?. Lancet 350 (1997), 430–436.
66. Ridker, P.M., Kundsin, R.B., Stampfer, M.J., Poulin, S., Hennekens, C.H., Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 99 (1999), 1161–1164.
67. Ridker, P.M., Are associations between infection and coronary disease causal or due to confounding?. Am J Med 106 (1999), 376–377.
68. Kalayoglu, M.V., Libby, P., Byrne, G.I., Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288 (2002), 2724–2731.
69. Andraws, R., Berger, J.S., Brown, D.L., Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293 (2005), 2641–2647.
70. Cheng, Y.J., Nie, X.Y., Chen, X.M., et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66 (2015), 2173–2184.
71. Sessa, R., Pietro, M.D., Filardo, S., Turriziani, O., Infectious burden and atherosclerosis: a clinical issue. World J Clin Cases 2 (2014), 240–249.
72. Martu, S., Nicolaiciuc, O., Solomon, S., et al. The evaluation of the C reactive protein levels in the context of the periodontal pathogens presence in cardiovascular risk patients. Rev Chim 68 (2017), 1081–1084.
73. Amar, S., Wu, S.C., Madan, M., Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J Immunol 182 (2009), 1584–1592.
74. Amar, S., Gokce, N., Morgan, S., Loukideli, M., Van Dyke, T.E., Vita, J.A., Periodontal disease is associated with brachial artery endothelial dysfunction and systemic inflammation. Arterioscler Thromb Vasc Biol 23 (2003), 1245–1249.
75. Sorrentino, R., Yilmaz, A., Schubert, K., et al. A single infection with Chlamydia pneumoniae is sufficient to exacerbate atherosclerosis in ApoE deficient mice. Cell Immunol 294 (2015), 25–32.
76. Chi, H., Messas, E., Levine, R.A., Graves, D.T., Amar, S., Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 110 (2004), 1678–1685.
77. Yuan, H., Zelkha, S., Burkatovskaya, M., Gupte, R., Leeman, S.E., Amar, S., Pivotal role of NOD2 in inflammatory processes affecting atherosclerosis and periodontal bone loss. Proc Natl Acad Sci U S A 110 (2013), E5059–E5068.
78. Li, L., Messas, E., Batista, E.L. Jr., Levine, R.A., Amar, S., Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 105 (2002), 861–867.
79. Modh, R.S., Jathal, B., Gupta, S., Patel, V., Sahayata, V., Periodontal diseases contribution to cardiovascular disease: an update on the associations and risk. Res Rev 8 (2017), 18–25.
80. Mach, F., Sukhova, G.K., Michetti, M., Libby, P., Michetti, P., Influence of Helicobacter pylori infection during atherogenesis in vivo in mice. Circ Res 90 (2002), E1–E4.
81. Fleet, J.C., Clinton, S.K., Salomon, R.N., Loppnow, H., Libby, P., Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae. J Nutr 122 (1992), 294–305.
82. Violi, F., Cangemi, R., Calvieri, C., Pneumonia, thrombosis and vascular disease. J Thromb Haemost 12 (2014), 1391–1400.
83. Aron-Wisnewsky, J., Clement, K., The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol 12 (2016), 169–181.
84. Tang, W.H., Kitai, T., Hazen, S.L., Gut microbiota in cardiovascular health and disease. Circ Res 120 (2017), 1183–1196.
85. Jonsson, A.L., Backhed, F., Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 14 (2017), 79–87.
86. Mogensen, T.H., Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22 (2009), 240–273.
87. Doherty, T.M., Shah, P.K., Arditi, M., Lipopolysaccharide, toll-like receptors, and the immune contribution to atherosclerosis. Arterioscler Thromb Vasc Biol, 25, 2005, e38 author reply e38–9.
88. van de Veerdonk, F.L., Netea, M.G., Dinarello, C.A., Joosten, L.A., Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32 (2011), 110–116.
89. Strowig, T., Henao-Mejia, J., Elinav, E., Flavell, R., Inflammasomes in health and disease. Nature 481 (2012), 278–286.
90. Paramel Varghese, G., Folkersen, L., Strawbridge, R.J., et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc, 5, 2016.
91. Prochnicki, T., Latz, E., Inflammasomes on the crossroads of innate immune recognition and metabolic control. Cell Metab 26 (2017), 71–93.
92. Clayton, T.C., Thompson, M., Meade, T.W., Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 29 (2008), 96–103.
93. Corrales-Medina, V.F., Alvarez, K.N., Weissfeld, L.A., et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 313 (2015), 264–274.
94. Restrepo, M.I., Reyes, L.F., Pneumonia as a cardiovascular disease. Respirology 23 (2018), 250–259.
95. Feldman, C., Anderson, R., Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest 148 (2015), 523–532.
96. Ivey, K.S., Edwards, K.M., Talbot, H.K., Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol 71 (2018), 1574–1583.
97. Kwong, J.C., Schwartz, K.L., Campitelli, M.A., et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 378 (2018), 345–353.
98. Frobert, O., Gotberg, M., Angeras, O., et al. Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial. Am Heart J 189 (2017), 94–102.
99. Vardeny, O., Udell, J.A., Joseph, J., et al. High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: rationale and design of the INVESTED trial. Am Heart J 202 (2018), 97–103.
100. Shah, P.K., Chyu, K.Y., Dimayuga, P.C., Nilsson, J., Vaccine for atherosclerosis. J Am Coll Cardiol 64 (2014), 2779–2791.
101. Gistera, A., Hermansson, A., Strodthoff, D., et al. Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis. J Intern Med 281 (2017), 383–397.
102. Tardif J-C, L'Allier P. Colchicine Cardiovascular Outcomes Trial (COLCOT). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02551094. Accessed August 30, 2018.
103. Everett, B.M., Pradhan, A.D., Solomon, D.H., et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166 (2013), 199–207.
104. Ridker, P.M., Thuren, T., Zalewski, A., Libby, P., Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162 (2011), 597–605.
105. Thompson PL. The LoDoCo2 trial: low dose colchicine for secondary prevention of cardiovascular disease. Available at: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363771. 2014. Accessed August 30, 2018.
106. Arditi, M., Shah, P.K., STOP the TRAFfic and Reduce the Plaque. J Am Coll Cardiol 71 (2018), 543–546.
107. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
108. Libby, P., Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 70 (2017), 2278–2289.
109. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
110. Ridker, P.M., A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol 67 (2016), 712–723.
111. Ridker, P.M., MacFadyen, J.G., Everett, B.M., et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391 (2018), 319–328.
112. Sarwar, N., Butterworth, A.S., Freitag, D.F., et al. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379 (2012), 1205–1213.
113. Swerdlow, D.I., Holmes, M.V., Kuchenbaecker, K.B., et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379 (2012), 1214–1224.